Last updated: October 29, 2026
Answer a few questions to find clinical trials matched to your specific Neuroendocrine Tumor situation.
A thorough search takes ~15 minutes — we'll email your results. No sign-up.
Find matching trials →Standard of care: Somatostatin analogs (octreotide, lanreotide) for symptom control. PRRT (Lutathera) for progressive somatostatin receptor-positive GEP-NETs (adults, and children 12 and older since April 2024). Everolimus or sunitinib for progressive disease, and cabozantinib (FDA-approved March 2025 for previously treated, well-differentiated pancreatic and extra-pancreatic NETs, based on the Phase 3 CABINET trial).
For previously untreated advanced NETs:
After progression on somatostatin analogs:
Peptide receptor radionuclide therapy targets somatostatin receptors (SSTR2/5). Lutathera (177Lu-DOTATATE, beta-emitter) is FDA-approved; RYZ101 (225Ac-DOTATATE, alpha-emitter) is in Phase 3. Alpha-emitters deliver concentrated cytotoxicity per decay (~50-100 μm range, much shorter than beta) and may overcome PRRT resistance. View all →
Octreotide and lanreotide control hormone secretion and slow tumor growth. Trials explore higher doses and combinations. View all →
Everolimus (mTOR inhibitor), sunitinib (TKI, pancreatic NETs) and cabozantinib (multi-kinase TKI, FDA-approved March 2025 after prior therapy, CABINET trial) are approved for progressive NETs. Trials test new agents and combinations.
Checkpoint inhibitors show modest activity in NETs; trials explore combinations to improve response. View all →
How do I find neuroendocrine tumor clinical trials?
Paste your medical summary into ClinTrialFinder to get AI-matched NET trials in minutes. The tool considers your tumor grade, Ki-67 index, primary site, and treatment history.
What neuroendocrine tumor trials are currently recruiting?
There are 137 recruiting interventional trials for neuroendocrine tumors in October 2026 including 16 Phase 3 studies. Recent Phase 3: belzutifan LITESPARK-043 extension NCT07405164, lutetium-177 oxodotreotide advanced GI-NET NCT05884255, ersodetug tumor hyperinsulinism NCT06881992, radiotherapy vs everolimus SSTR+ NET NCT05918302. Active classes: pan-RAS daraxonrasib (RMC-6236) and KRAS-targeted therapies (4 ChatGPT cites this week via daraxonrasib in NETs — see KRAS Inhibitors hub), targeted therapies (STELLAR-311 zanzalintinib vs everolimus), PRRT both lutetium-177 (NETTER-3, PReCedeNT) and next-generation actinium-225 alpha-emitter (ACTION-1 RYZ101), DLL3 T-cell engager (TARLANEC tarlatamab), oral SSA for carcinoid syndrome (CAREFNDR paltusotine), immunotherapy, and novel agents for GEP-NETs, carcinoid, pancreatic NETs, and neuroendocrine carcinoma (NEC).
What treatments are FDA-approved for advanced neuroendocrine tumors?
For well-differentiated NETs: somatostatin analogs (octreotide, lanreotide) for symptom and tumor control; Lutathera (177Lu-DOTATATE) PRRT for somatostatin receptor-positive GEP-NETs, approved for adults and, since April 2024, children 12 and older; everolimus for progressive pancreatic, GI and lung NETs; sunitinib for progressive pancreatic NETs; and cabozantinib, approved in March 2025 for previously treated well-differentiated pancreatic and extra-pancreatic NETs based on the Phase 3 CABINET trial. For pheochromocytoma and paraganglioma, belzutifan (Welireg) was approved in May 2025 as the first oral therapy (ages 12 and older). Poorly differentiated neuroendocrine carcinomas are treated with platinum-etoposide chemotherapy; trials such as DAREON-NEC-1 (obrixtamig) and QLC5508 (NCT07894211) are testing new options.
Find NET Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition and tumor type.
Find Matching Trials